How many insider trades does FilingIQ track for PYXS?

FilingIQ tracks 77 Form 4 insider transactions for PYXS (Pyxis Oncology, Inc.), covering filings from Oct 7, 2021 onwards. 9 of those were filed in the last 90 days.

Are PYXS insiders net buyers or net sellers?

Across the full Form 4 history for PYXS, 15 transactions (19%) were open-market purchases and 9 (12%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.

Where does PYXS insider data come from?

Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.

What sector is PYXS in?

Pyxis Oncology, Inc. (PYXS) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $80.94M.

PYXS insider trading

Healthcare

Pyxis Oncology, Inc. — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.

Total Form 4 trades

Last 90 days

Buys / sells

19% / 12%

Market cap

$80.94M

About Pyxis Oncology, Inc.

Pyxis Oncology, Inc., a clinical stage company, engages in the development of therapeutics to treat solid tumors. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors. The company is also developing PYX-107, a CD40 agonist with demonstrated anti-cancer activity in patients with several cancer indications, which is in Phase 2 clinical trial for the treatment of tumors, such as soft tissue sarcomas, esophageal and gastroesophageal junction, cancers, and pancreatic ductal adenocarcinoma. It has in-license agreement with Pfizer Inc. to develop and commercialize ADC product candidates, including micvotabart pelidotin and PYX-203, and other ADC product candidates directed to the licensed targets; and Biosion USA, Inc. for development, manufacture, and commercialization of PYX-106, an IO product candidate. Pyxis Oncology, Inc. was incorporated in 2018 and is headquartered in Boston, Massachusetts.

Company website: www.pyxisoncology.com

PYXS insider activity at a glance

FilingIQ has scored 77 insider transactions for PYXS since Oct 7, 2021. The most recent filing in our index is dated Mar 24, 2026.

Across the full history, 15 open-market purchases and 9 open-market sales were filed under transaction codes P and S respectively. Compensatory share awards (code A) and option exercises (code M) are tracked separately and not counted here.

The average FilingIQ composite score on PYXS insider trades is 55.5/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.

View live PYXS trades on FilingIQ Raw filings on SEC EDGAR

Other Healthcare tickers with recent insider activity

UTHR 1,098

UNITED THERAPEUTICS Corp

APLS 279

Apellis Pharmaceuticals, Inc.

KMDA 218

KAMADA LTD

BMY 185

BRISTOL MYERS SQUIBB CO

ADPT 184

Adaptive Biotechnologies Corp

GH 169

Guardant Health, Inc.

ISRG 166

INTUITIVE SURGICAL INC

VTRS 165

Viatris Inc

13F funds holding PYXS

Decheng Capital Management III (Cayman), LLC

$650352 · 0.2% of AUM

Frequently asked

How many insider trades does FilingIQ track for PYXS?: FilingIQ tracks 77 Form 4 insider transactions for PYXS (Pyxis Oncology, Inc.), covering filings from Oct 7, 2021 onwards. 9 of those were filed in the last 90 days.
Are PYXS insiders net buyers or net sellers?: Across the full Form 4 history for PYXS, 15 transactions (19%) were open-market purchases and 9 (12%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
Where does PYXS insider data come from?: Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
What sector is PYXS in?: Pyxis Oncology, Inc. (PYXS) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $80.94M.

Methodology & sources

Every PYXS insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.